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Safety and immunogenicity of inactivated poliovirus vaccine 
when given with measles–rubella combined vaccine and 
yellow fever vaccine and when given via diﬀ erent 
administration routes: a phase 4, randomised, non-inferiority 
trial in The Gambia
Ed Clarke, Yauba Saidu, Jane U Adetifa, Ikechukwu Adigweme, Mariama Badjie Hydara, Adedapo O Bashorun, Ngozi Moneke-Anyanwoke, 
Ama Umesi, Elishia Roberts, Pa Modou Cham, Michael E Okoye, Kevin E Brown, Matthias Niedrig, Panchali Roy Chowdhury, Ralf Clemens, 
Ananda S Bandyopadhyay, Jenny Mueller, David J Jeﬀ ries*, Beate Kampmann*
Summary
Background The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio 
eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the measles–rubella 
and yellow fever vaccines at 9 months and when given as a full or fractional dose using needle and syringe or 
disposable-syringe jet injector.
Methods We did a phase 4, randomised, non-inferiority trial at three periurban government clinics in west Gambia. 
Infants aged 9–10 months who had already received oral poliovirus vaccine were randomly assigned to receive the IPV, 
measles–rubella, and yellow fever vaccines, singularly or in combination. Separately, IPV was given as a full 
intramuscular or fractional intradermal dose by needle and syringe or disposable-syringe jet injector at a second visit. 
The primary outcomes were seroprevalence rates for poliovirus 4–6 weeks post-vaccination and the rate of 
seroconversion between baseline and post-vaccination serum samples for measles, rubella, and yellow fever; and the 
post-vaccination antibody titres generated against each component of the vaccines. We did a per-protocol analysis with 
a non-inferiority margin of 10% for poliovirus seroprevalence and measles, rubella, and yellow fever seroconversion, 
and (⅓) log2 for log2-transformed antibody titres. This trial is registered with ClinicalTrials.gov, number NCT01847872.
Findings Between July 10, 2013, and May 8, 2014, we assessed 1662 infants for eligibility, of whom 1504 were enrolled 
into one of seven groups for vaccine interference and one of four groups for fractional dosing and alternative route of 
administration. The rubella and yellow fever antibody titres were reduced by co-administration but the seroconversion 
rates achieved non-inferiority in both cases (rubella, –4·5% [95% CI –9·5 to –0·1]; yellow fever, 1·2% [–2·9 to 5·5]). 
Measles and poliovirus responses were unaﬀ ected (measles, 6·8% [95% CI –1·4 to 14·9]; poliovirus serotype 1, 1·6% 
[–6·7 to 4·7]; serotype 2, 0·0% [–2·1 to 2·1]; serotype 3, 0·0% [–3·8 to 3·9]). Poliovirus seroprevalence was universally 
high (>97%) after vaccination, but the antibody titres generated by fractional intradermal doses of IPV did not achieve 
non-inferiority compared with full dose. The number of infants who seroconverted or had a four-fold rise in titres was 
also lower by the intradermal route. There were no safety concerns.
Interpretation The data support the future co-administration of IPV, measles–rubella, and yellow fever vaccines 
within the Expanded Programme on Immunization schedule at 9 months. The administration of single fractional 
intradermal doses of IPV by needle and syringe or disposable-syringe jet injector compromises the immunity 
generated, although it results in a high post-vaccination poliovirus seroprevalence.
Funding Bill & Melinda Gates Foundation.
Copyright © Clarke et al. Open Access article distributed under the terms of CC BY.
Introduction
The World Health Assembly declared its commitment to 
global polio eradication in 1988, at a time when an estimated 
350 000 people were paralysed annually as a result of the 
infection. Since then, major strides have been made and 
the incidence of polio has fallen by more than 99% to the 
point where fewer than 75 cases of paralytic polio associated 
with wild-type infection were reported worldwide in 2015.1,2
In 2012, the Strategic Advisory Group of Experts on 
Immunisation (SAGE), the global policy-making body 
for vaccination, recommended the withdrawal of the 
type 2 component of the oral poliovirus vaccine (OPV) 
from routine immunisation, leading to the replacement 
of trivalent OPV with bivalent OPV in April, 2016.3 The 
switch comes after the eradication of wild-type 2 
poliovirus in 1999 and represents a crucial step in the 
Lancet Glob Health 2016; 
4: e534–47
Published Online
June 27, 2016
http://dx.doi.org/10.1016/
S2214-109X(16)30075-4
*Joint senior authors
MRC Unit The Gambia, Fajara, 
Banjul, The Gambia 
(E Clarke MBChB, Y Saidu MD, 
J U Adetifa MD, 
I Adigweme MBBS, 
M Badjie Hydara MBBS, 
A O Bashorun MBBS, 
N Moneke-Anyanwoke MBBS, 
A Umesi MBBS, E Roberts BSc, 
P M Cham BSc, M E Okoye MBBS, 
J Mueller MD, D J Jeffries PhD, 
Prof B Kampmann MD); 
Department of Medicine, 
Imperial College, London, UK 
(Prof B Kampmann); Virus 
Reference Department, Public 
Health England, Colindale, UK 
(K E Brown MBBS); Centre for 
Biological Threats and Special 
Pathogens, Robert Koch 
Institut, Berlin, Germany 
(Prof M Niedrig PhD, 
P R Chowdhury MSc); Global 
Research in Infectious Diseases, 
Rio de Janeiro, Brazil 
(R Clemens MD); and Bill & 
Melinda Gates Foundation, 
Seattle, USA 
(A S Bandyopadhyay MBBS)
Correspondence to:
Dr Ed Clarke, Vaccines and 
Immunity Theme, MRC Unit 
The Gambia, PO Box 273, Banjul, 
The Gambia
eclarke@mrc.gm
Articles
e535 www.thelancet.com/lancetgh   Vol 4   August 2016
endgame strategy, because more than 90% of circulating 
vaccine-derived polioviruses (and approximately 30% of 
vaccine-associated paralytic polio) are of this virus type.3 
To maintain population priming against the type 2 
virus, the switch has been accompanied by the 
introduction of a dose of the (trivalent) inactivated 
poliovirus (IPV). This is being given concomitantly with 
the third dose of bivalent OPV at 3–4 months of age in 
most countries that use the recommended Expanded 
Programme on Immunization (EPI) schedule.4 If a 
second dose is recommended, as is likely in countries at 
risk of outbreaks in advance of ﬁ nal OPV cessation, 
its administration alongside the measles–rubella 
combined vaccine and the yellow fever vaccine at 
9 months would be favourable given the availability of 
supportive safety and immunogenicity data.
At the time of widespread IPV introduction, fractional 
intradermal doses of IPV represent an important option 
to reduce both the manufacturing scale-up required and 
the costs involved. The delivery of the vaccine using a 
disposable-syringe jet injector also has the potential to 
facilitate rapid campaign-based delivery of IPV, for 
example in the context of an outbreak of type 2 
circulating vaccine-derived poliovirus. An intramuscular 
booster dose of IPV after OPV priming has previously 
been shown to result in high seroconversion rates, 
Research in context
Evidence before this study
We did a PubMed search to identify articles published in any 
language before Jan 31, 2016. We used the following terms with 
appropriate Boolean operators: [objective 1] “inactivated 
poliovirus vaccine”, “measles”, “rubella”, “yellow fever”, 
“vaccin*”, “immun*”, “co-administration”, “concomitant”, 
“interference”; [objective 2] “inactivated poliovirus vaccine”, 
“intradermal”, “fractional dose”, “device”, “jet inject*”, 
“disposable syringe jet inject*”. Reference lists were reviewed 
for additional publications. No trials or studies have examined 
the co-administration of the measles–rubella vaccine with the 
yellow fever vaccine or the co-administration of the 
single-component inactivated poliovirus vaccine (IPV) with 
either the measles–rubella or the yellow fever vaccine. 
Three studies, all undertaken in west and central Africa, have 
examined the co-administration of the single-component 
measles vaccine and the yellow fever vaccine. None 
demonstrated any interference between these vaccines in 
infants aged 6–12 months. By contrast, a single study 
undertaken in Brazil examined the co-administration of a 
three-component measles, mumps, and rubella (MMR) vaccine 
and the yellow fever vaccine; its ﬁ ndings showed decreased 
seroconversion for yellow fever, rubella, and mumps, but no 
eﬀ ect on measles seroconversion associated with 
co-administration. Rubella and yellow fever geometric mean 
antibody titres were also reduced. No trials or studies have 
previously been reported from sub-Saharan Africa exploring 
either fractional doses of IPV or the use of disposable-syringe jet 
injector (DSJI) to administer IPV in any age group. Two trials, 
one undertaken in India and the other in Cuba, have examined 
fractional doses of IPV in oral poliovirus vaccine-primed infants. 
The trial in Cuba included groups who received IPV via needle 
and syringe, as well as groups with vaccine administered by 
DSJI, whereas the trial in India included only DSJI-based 
intradermal IPV administration. In both cases, the response to 
the fractional intradermal doses of IPV was lower than the 
responses to the full intramuscular dose. In the trial in Cuba, the 
responses to the needle and syringe and DSJI-based intradermal 
administration routes were similar. The use of an intramuscular 
DSJI to administer IPV has not been reported. To our knowledge, 
this is the ﬁ rst report identiﬁ ed describing the use of the 
intramuscular DSJI to vaccinate children younger than 1 year.
Added value of this study
This study provides the ﬁ rst data for the safety and 
immunogenicity of co-administering the measles–rubella and 
yellow fever vaccines, and also on the additional eﬀ ect of IPV 
co-administration in 9–10-month old infants. Although the 
antibody concentrations for rubella and yellow fever were 
reduced by vaccine co-administration, the seroconversion rates 
were consistently maintained within a –10% non-inferiority 
margin. Co-administration had no eﬀ ect on the measles and 
poliovirus serological responses and there were no safety 
concerns. These are also the ﬁ rst data reported from 
sub-Saharan Africa on the administration of fractional 
intradermal doses of IPV. In this setting, such fractional doses of 
the vaccine result in lower antibody titres and few infants 
experiencing a four-fold rise compared with a full intramuscular 
dose. Nonetheless, most infants who remained seronegative 
after serial doses of OPV were likely to seroconvert. Full-dose 
IPV can be safely and eﬀ ectively administered to children 
younger than 1 year using a DSJI.
Implications of all the available evidence
Our data open the way for the inclusion of a dose of IPV within 
the infant immunisation schedule alongside the measles–rubella 
and yellow fever vaccines at 9–12 months of age across 
sub-Saharan Africa and South America, and also for the addition 
of IPV to the measles–rubella vaccine administered to infants in 
those parts of the world in which yellow fever is non-endemic. 
A second dose of IPV at this age will probably induce more 
sustained protection than a second dose within the infant 
priming schedule, and thus is likely to be favoured if high 
coverage can be obtained. The supply beneﬁ ts as well as reduced 
costs of administering fractional intradermal doses of IPV make 
such an approach attractive, although it will result in a 
compromise in the serological protection generated in the 
population. However, it should result in the seroconversion of 
most seronegative infants and may therefore be considered in 
campaigns and outbreak control.
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whereas the seroconversion rates and more particularly 
the antibody titres generated after fractional-dose IPV 
administration are reduced in most studies, which until 
now have all been done outside sub-Saharan Africa.5–12
We undertook a randomised, controlled trial with two 
objectives. First, we aimed to assess for interference 
associated with the co-administration of IPV, measles–
rubella vaccine, and yellow fever vaccine, and to conﬁ rm 
the safety of co-administration. Second, we aimed to 
compare the immunogenicity and safety of intramuscular 
full-dose (0·5 mL) IPV and intradermal fractional-dose 
(0·1 mL) IPV, delivered using either needle and syringe 
or disposable-syringe jet injector.
Given the logistical and cost beneﬁ ts of co-
administering IPV with the other vaccines at 9 months, 
and of fractional dosing and administration with 
disposable-syringe jet injector, a non-inferiority design 
was used to assess the primary immunogenicity 
endpoints.
Methods
Study design and participants
We did a phase 4, single-centre, randomised, laboratory-
observer-blind, non-inferiority trial in the periurban 
west coast of The Gambia. Infants attending three typical 
government clinics for their EPI immunisations were 
recruited. Information regarding the trial was provided in 
these clinics and parents expressing an interest were 
invited to nearby clinical trial facilities for consent 
discussions.
To be eligible, infants had to be aged 9–10 months 
(inclusive); to have received at least three doses of 
trivalent OPV up to 28 days before recruitment; to have 
not received any measles, rubella, yellow fever, or 
inactivated poliovirus vaccines; and to be clinically 
healthy with no indications of clinically signiﬁ cant 
chronic health problems (appendix).
The study was approved by The Gambia Government/
MRC Joint Ethics Committee and the Medicines Board of 
The Republic of The Gambia. It was conducted according 
to the ICH Harmonised Tripartite Guideline for Good 
Clinical Practice and local ethical and regulatory 
requirements.
A parent provided written or thumb-printed informed 
consent for their oﬀ spring to take part in the study. Most 
parents were not literate in English, in which case an 
impartial witness was present throughout the informed 
consent discussion, undertaken in one of the local 
languages, and signed to attest to the completeness of 
the information given.
Randomisation and masking
Enrolled infants were randomly assigned into one of 
eight study groups using pre-prepared, sequentially 
numbered, sealed envelopes to maintain allocation 
concealment. The randomisation list was electronically 
generated with a block size of 32 and was stratiﬁ ed by 
sex and by the clinic where the infant was recruited. 
Randomisation was undertaken by a study clinician 
after conﬁ rmation of eligibility. Neither the parents nor 
ﬁ eld team were masked to randomisation group, 
because double-dummy placebo injections (as would 
have been required to achieve blinding) were not 
considered to be ethically justiﬁ ed. Laboratory personnel 
generating and analysing serological data were masked 
to treatment allocation.
Procedures
At visit one, infants received the IPV, measles–rubella, 
and yellow fever vaccines either singularly, in 
combinations of two, or all three vaccines given together, 
according to the schedule outlined in ﬁ gure 1 and the 
appendix. The measles–rubella and yellow fever vaccines 
were administered as single 0·5 mL intramuscular 
injections into the left thigh, and the IPV as a single 
0·5 mL intramuscular injection into the right thigh 
using a 23G/25 mm needle.
At visit two, those infants who had not received IPV at 
visit one received the vaccine into the right thigh either 
as a full-dose (0·5 mL) intramuscular injection using a 
23G/25 mm needle; as a fractional-dose (0·1 mL) 
intradermal injection using a 26G/10 mm needle; 
as a full dose (0·5 mL) using an intramuscular 
disposable-syringe jet injector (Stratis; Pharmajet, 
Golden, CO, USA); or as a fractional dose (0·1 mL) 
using an intradermal disposable-syringe jet injector 
(Tropis; Pharmajet). Details of the vaccines are provided 
in the appendix.
Infants were observed for 30 min after vaccination 
and immediate reactogenicity data were collected. 
Reactogenicity data were also collected during home 
visits done on days one to three after vaccinations in 
which routes of IPV administration were investigated, 
and on day three after other vaccinations. Data on adverse 
events and serious adverse events were collected 
throughout the study.
Blood samples for baseline and post-vaccination serology 
were collected by peripheral venepuncture and separated 
and stored at –70°C within 6 h. Poliovirus, measles, and 
rubella serology was undertaken in the Virus Reference 
Department (Public Health England Laboratories, 
Colindale, UK). Yellow fever serology was undertaken at 
the Robert Koch Institute (Berlin, Germany).
Neutralising antibody titres against poliovirus types 1, 
2, and 3 were assessed using neutralisation assays as 
previously described.13 Serial two-fold dilutions from a 
starting dilution of one in eight were undertaken until an 
endpoint titre was attained. Seropositivity was deﬁ ned as 
a reciprocal neutralising antibody titre of eight or more. 
Measles and rubella IgG antibody concentrations were 
determined using a commercial enzyme-linked 
immunosorbent assay (Enzygnost anti-measles and 
anti-rubella virus IgG; Siemens, Munich, Germany). 
Seropositivity for measles was deﬁ ned as an IgG 
See Online for appendix
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1662 assessed for eligibility
1504 enrolled
188 received IPV† 189 received MR† 187 received YF* 186 received IPV
 and MR
185 received IPV
 and YF
188 received MR
 and YF
191 received IPV,
 MR, and YF
190 received MR
178 included in 
 per-protocol 
 analysis of 
 IPV (IM NS)
168 included in 
 per-protocol 
 analysis of 
 IPV (IM DSJI)
177 included in 
 per-protocol 
 analysis of 
 IPV (ID NS)
177 included in 
 per-protocol 
 analysis of 
 IPV (IM DSJI)
182 included in 
 per-protocol 
 analysis of IPV
183 included in 
 per-protocol 
 analysis of MR
180 included in 
 per-protocol 
 analysis of YF
181 included in 
 per-protocol 
 analysis of 
 IPV and MR
175 included in 
 per-protocol 
 analysis of 
 IPV and YF
182 included in 
 per-protocol 
 analysis of 
 MR and YF
184 included in 
 per-protocol 
 analysis of IPV,
 MR, and YF
Not analysed
1 consent 
 withdrawn
3 visit window
2 serology
3 consent 
 withdrawn
2 lost to follow-up
1 protocol
 deviation
3 visit window
4 serology
1 consent 
 withdrawn
1 lost to follow-up
1 death
2 visit window
2 serology
2 visit window
5 serology
188 included in 
 safety analysis
189 included in 
 safety analysis
187 included in 
 safety analysis
186 included in 
 safety analysis
185 included in 
 safety analysis
188 included in 
 safety analysis
191 included in 
 safety analysis
190  included in 
 safety analysis 
184 received IPV
 (IM NS)‡
181 received IPV
 (IM DSJI)
184 received IPV
 (ID NS)
184 received IPV
 (ID DSJI)
1 lost to 
 follow-up
1 protocol 
 deviation
3 visit window
1 serology
3 consent 
 withdrawn
1 lost to 
 follow-up
1 protocol 
 deviation
1 serology*
3 consent 
 withdrawn
1 lost to 
 follow-up 
2 protocol 
 deviation
1 visit window†
3 consent 
 withdrawn
2 protocol 
 deviation
3 consent 
 withdrawn
2 lost to 
 follow-up
3 visit window
2 serology*
3 consent 
 withdrawn
1 protocol 
 deviation
2 visit window
3 consent 
 withdrawn
1 lost to 
 follow-up
1 visit window
2 serology
2 consent 
 withdrawn
2 lost to 
 follow-up
1 protocol 
 deviation
1 death
1504 randomised
158 total ineligible
 30 inclusion criteria not met
 11 receipt of at least 3 doses of trivalent OPV
 19 other 
 128 met exclusion criteria
 48 severe protein-energy malnutrition
 25 signiﬁcant chronic health problem or congenital defect
 11 previous receipt on measles, rubella, yellow fever or IPV
 8 suspected or conﬁrmed immune deﬁciency
 36 other
Vaccination visit 1 (concomitant administration)
Vaccination visit 2 (alternative routes)
Analysis after vaccination visit 2
Analysis after vaccination visit 1
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concentration of 150 IU/mL or more and for rubella as an 
IgG concentration of 4 IU/mL or more. Yellow 
fever neutralisation titres were determined using the 
microneutralisation test as previously described.14 Serial 
two-fold dilutions were undertaken from a starting 
dilution of one in four, up to a dilution of one in 256. 
Seropositivity for yellow fever was deﬁ ned as a reciprocal 
neutralising antibody titre of eight or more.
Outcomes
The eﬀ ects of vaccine co-administration (objective one) 
were assessed through the vaccines administered at visit 
one. Interference was identiﬁ ed by comparing the study 
groups which received IPV, measles–rubella vaccine, or 
yellow fever vaccine alone with those in which the vaccines 
were given in combination. Baseline serum samples were 
taken before vaccination and post-vaccination samples 
were taken at visit two, 4–6 weeks later.
The response to IPV administered as a full intra-
muscular dose or as a fractional intradermal dose, using 
either needle and syringe or disposable-syringe jet 
injector (objective two), was assessed through the 
vaccines administered at visit two. Infants in groups that 
did not receive IPV at visit one had a baseline sample 
for poliovirus serology taken at visit two, before IPV 
administration, and a post-vaccination sample taken at 
visit three, 4–6 weeks later.
Baseline and post-vaccination seroprevalence, rates of 
seroconversion (seronegative to seropositive), and the 
number of seropositive infants who had a four-fold rise 
in antibodies after vaccination were generated for each 
vaccine antigen. The total response, combining the 
percentage of infants who seroconverted and the 
percentage who experienced a four-fold antibody rise, 
was also calculated.
The primary endpoints for the assessment of 
non-inferiority were the post-vaccination seroprevalence 
rates for poliovirus and the rate of seroconversion 
between the baseline and the post-vaccination sample for 
measles, rubella, and yellow fever (S); and also the post-
vaccination antibody titres (T) generated against each 
component of the vaccines. For the purposes of assessing 
vaccine interference the reference responses (SREF and 
TREF) against which non-inferiority was assessed were 
those generated when each of the vaccines was 
administered on its own. When assessing the alternative 
modes of IPV delivery, the responses generated after 
0·5 mL intramuscular needle and syringe-based 
administration at visit two represented the reference. 
The responses generated after vaccine co-administration 
and after fractional-dose intradermal IPV administration 
with needle and syringe as the primary analyses, and IPV 
administration with disposable-syringe jet injector as 
secondary analyses, represented the investigational 
responses (SINV and TINV). A secondary non-inferiority 
analysis was also undertaken on the total response data.
The primary safety outcomes were the occurrence of 
serious adverse events throughout an infant’s enrolment in 
the trial; local and systemic adverse reactions collected on 
days zero to three after administration via disposable-syringe 
jet injector, and comparator IPV administration with 
needle and syringe; also on day zero and day three after the 
singularly and co-administered vaccines.
Statistical analysis
The non-inferiority analysis was undertaken on the 
per-protocol population described in ﬁ gure 1. 
Non-inferiority of the response to each vaccine 
component was declared if the lower limit of the 95% CI 
of the diﬀ erence in responses (SINV–SREF) was greater 
than the –10% non-inferiority margin. The margin was 
determined on the basis of considered public health 
eﬀ ects of such a reduction compared with the potential 
logistical and cost beneﬁ ts of co-administration and of 
the alternative modes of IPV delivery, and is consistent 
with available regulatory guidance.15,16
We calculated that 188 infants per group (1504 infants 
in total) would be required to provide 80% power to 
demonstrate non-inferiority. This was based on a 
reference and investigational group response rate of 
90% taken from published reports,5,17 a one-sided α of 
0·025, and a 20% margin for participant attrition. This 
sample size provided 92% power to determine the non-
inferiority of the antibody titres if the lower limit of the 
95% CI for the diﬀ erence between log2-transformed 
titres (TINV–TREF) was greater than the (⅓) log2 non-
inferiority margin assuming a non-parametric Mann-
Whitney test. The 95% CIs for the point diﬀ erence 
(SINV–SREF) were estimated using the Wilson score 
interval.18 The titre data were log2-transformed and if 
normality and constant variance assumptions were 
satisfactory the 95% CI for the diﬀ erences between the 
mean log2-transformed titres (TINV–TREF) were estimated 
via the pooled variance from a two-sample t test. The 
non-inferiority inference was corroborated by estimating 
non-parametric CIs on the basis of the Hodges-Lehman 
Figure 1: Trial proﬁ le
At visit one, infants received IPV, measles–rubella vaccine, and yellow fever vaccine 
either singularly, in combinations of two (IPV and measles–rubella, IPV and yellow 
fever, or measles–rubella and yellow fever) or all three vaccines given together. 
This allowed interference between the vaccines associated with co-administration 
to be assessed (objective one). An eighth group, who received the measles–rubella 
vaccine at visit one, was required to provide four groups at visit two who had not 
previously received IPV. This allowed the alternative routes of administration and 
the disposable-syringe jet injector devices to be assessed (objective two). 
The additional group was not included in the immunogenicity assessment for 
objective one. At visit two, infants in the four groups for IPV administration route 
received the vaccine either as a full (0·5 mL) intramuscular dose or as a fractional 
(0·1 mL) intradermal dose, using either a needle and syringe or a 
disposable-syringe jet injector device. IPV=inactivated poliovirus vaccine. 
MR=measles–rubella. YF=yellow fever. IM=intramuscular. NS=needle and syringe. 
ID=intradermal. DSJI=disposable-syringe jet injector. *Excluded from the 
per-protocol population for vaccine co-administration due to missing a visit 
window (n=1) or as a result of not having a complete set of serology results (n=3), 
but included in the analysis related to the alternative routes (the deviations had 
no eﬀ ect on the assessment of the second objective). †Reference groups for 
objective one. ‡Reference group for objective two.
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median diﬀ erence. Interval regression was done to test 
for non-inferiority of the measles antibody con-
centrations given the proportion of left-censored 
seronegative data. Responses were declared inferior if 
the upper limit of the 95% CI for the diﬀ erences 
between the investigational and reference responses 
were below the non-inferiority margin.
Objectives one and two are distinct and do not aﬀ ect 
each other, therefore correction for multiplicity between 
these objectives was not required. To reﬂ ect the expected 
requirement for the responses to each vaccine antigen to 
be maintained for their future co-administration to be 
recommended, individual non-inferiority tests were 
subsequently combined using the intersection union 
test.19 Thus, for global non-inferiority to be declared for a 
given vaccine combination, non-inferiority had to be 
achieved individually for each component of the 
co-administered vaccines. This is conservative in terms 
of the type I error rate. No formal power calculation was 
undertaken for this intersection union test approach 
because the dependence structure between the within-
subject serological responses was unknown, and an 
independence assumption was highly unlikely. However, 
the margin for participant attrition and the group 
response rates used in calculating the power of individual 
non-inferiority tests were conservative.
For objective two, a primary comparison was 
undertaken between the intramuscular and intradermal 
administration routes based on needle and syringe, 
reﬂ ecting the key policy decision in the ﬁ eld currently. 
Comparisons between the needle and syringe route, 
versus the disposable-syringe jet injector route, were 
secondary analyses.
Data were extracted using SQL queries and summary 
statistics and analyses were generated in Matlab 
(release R2014b) and Stata (release 12.1). A data and 
safety monitoring board (DSMB) reviewed safety data 
throughout the trial. The trial was registered with 
ClinicalTrials.gov, number NCT01847872, where the trial 
protocol is available.
Role of the funding source
The trial was sponsored by the Medical Research Council 
and funded by the Bill & Melinda Gates Foundation 
(BMGF). A BMGF employee (ASB) participated in the 
study design, data interpretation, and decision to submit 
for publication. The corresponding author had full access 
to all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
The ﬁ rst infant was enrolled on July 10, 2013, and the 
last infant completed the study on May 8, 2014. 
Enrolment was temporarily halted between Oct 22 and 
Dec 2, 2013, after a national trivalent OPV campaign 
including infants enrolled in the trial within the target 
age group. No infants enrolled in the study at the time 
received a dose of trivalent OPV during the campaign 
and any eﬀ ect of environmental exposure on systemic 
immunity is likely to be minimal in the context of a 
recent dose of IPV; any eﬀ ect would also be evenly 
distributed between groups.
A total of 1662 infants were assessed for eligibility. 
After screening, 158 infants were deemed to be 
ineligible and 1504 infants were randomised (ﬁ gure 1). 
Immunogenicity was analysed in the per-protocol 
IPV at visit 1 
(n=188)
Measles–rubella 
at visit 1, IPV 
(IM NS) at visit 2 
(n=189)
Yellow fever at 
visit 1, IPV 
(IM DSJI) at 
visit 2 (n=187)
IPV and 
measles–rubella 
at visit 1 
(n=186)
IPV and yellow 
fever at visit 1 
(n=185)
Measles–rubella 
and yellow fever 
at visit 1, IPV 
(ID NS) at visit 2 
(n=188)
IPV, measles–
rubella, and 
yellow fever at 
visit 1 (n=191)
IPV (ID DSJI) at 
visit 2 (n=190)
Overall (n=1504)
Age, months 9·6 (9·0–11·0) 9·6 (9·0–11·0) 9·6 (9·0–11·0) 9·7 (9·0–11·0) 9·5 (9·0–11·0) 9·7 (9·0–11·0) 9·6 (9·0–11·0) 9·5 (9·0–11·0) 9·6 (9·0–11·0)
Male sex 89 (47%) 92 (49%) 90 (48%) 91 (49%) 90 (49%) 92 (49%) 94 (49%) 92 (48%) 730 (49%)
Weight, kg 8·1 (6·0–12·9) 8·1 (6·2–12·4) 8·1 (6·1–11·5) 8·2 (6·2–11·9) 8·2 (6·0–10·9) 8·1 (6·1–10·7) 8·1 (6·0–11·9) 8·2 (6·2–11·7) 8·2 (6·0–12·4)
Length, cm 70·4
(63·0–77·0)
70·7
(62·0–78·0)
70·5
(63·0–78·0)
70·8
(63·0–78·0)
70·7
(63·0–77·0)
70·4
(65·0–76·0)
70·5
(64·0–79·0)
70·6
(64·0–78·0)
70·6
(62·0–79·0)
Number of 
previous OPV 
doses*
4·9 (4·0–6·0) 5·0 (4·0–6·0) 4·8 (4·0–7·0) 5·0 (4·0–7·0) 4·9 (4·0–6·0) 4·9 (4·0–6·0) 4·9 (4·0–6·0) 4·9 (4·0–6·0) 4·9 (4·0–7·0)
Time since last 
OPV dose, days*
83·6
(29·0–192·0)
81·5
(29·0–190·0)
86·7
(28·0–191·0)
85·1
(20·0–222·0)
84·2
(34·0–182·0)
83·1
(31·0–192·0)
84·5
(30·0–190·0)
87·1
(28·0–196·0)
84·5
(20·0–222·0)
Mother’s tribe
Mandinka 102 (54%) 101 (53%) 105 (56%) 107 (58%) 100 (54%) 107 (57%) 96 (50%) 94 (49%) 812 (54%)
Wolof 23 (12%) 22 (12%) 20 (11%) 23 (12%) 24 (13%) 21 (11%) 21 (11%) 23 (12%) 177 (12%)
Fula 13 (7%) 14 (7%) 14 (7%) 11 (6%) 15 (8%) 13 (7%) 18 (9%) 21 (11%) 119 (8%)
Other 50 (27%) 52 (28%) 48 (26%) 45 (24%) 46 (25%) 47 (25%) 56 (29%) 52 (27%) 396 (26%)
Data are mean (range) or n (%). IPV=inactivated poliovirus vaccine. IM=intramuscular. NS=needle and syringe. DSJI=disposable-syringe jet injector. ID=intradermal. OPV=oral poliovirus vaccine. *Based on 
information recorded on the parent-held infant welfare card for routine doses and parent recall associated with knowledge of dates of national OPV campaigns for campaign-based doses. 
Table 1: Baseline characteristics
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population, after exclusion of participants due to 
consent withdrawal (parent withdrew consent for 
continued study participation after randomisation; 
n=25), loss to follow-up (all contact with family lost; 
n=11), protocol deviation (any deviation from the 
protocol which could, in theory, aﬀ ect the immuno-
genicity results obtained—eg, vaccines received outside 
protocol; n=3), ineligibility for randomisation (n=3), 
vaccination error (n=2), randomisation error (n=1), 
serum sample obtained outside the visit window period 
(n=20), required serology results not obtained for any 
reason (n=19), or death of infant during study 
participation (n=1). Of the 1314 infants in one of the 
seven groups included in the assessment of vaccine 
co-administration (objective one), 1267 (96%) were 
included in the per-protocol analysis. Of the 754 infants 
in one of the four groups in which the alternative 
modes of IPV delivery were subsequently assessed 
(objective two), 700 (93%) were included in the 
per-protocol analysis.
The demographic characteristics of the 1504 randomised 
infants are provided in table 1. 730 (49%) were male and 
all had received at least four doses of OPV. The baseline 
serological data in the seven groups considered in 
the assessment of vaccine interference are provided in 
table 2. Poliovirus seroprevalence rates ranged from 
86% to 92% for type 1, 96% to 97% for type 2, and 
71% to 86% for type 3 (table 2). Seroprevalence 
for measles ranged from zero to 1%, for yellow 
fever from 2% to 3%, and for rubella from 9% to 14% 
(table 2).
Summary statistics for the reference and investigational 
groups after vaccination are provided in table 3. 
Post-vaccination poliovirus seroprevalence ranged from 
98% to 100% for type 1, was consistently 100% for type 2, 
and ranged from 97% to 99% for type 3. The lower limit 
of the 95% CI (SINV–SREF) was above the –10% non-
inferiority margin in all cases and non-inferiority was 
thus demonstrated (rubella, –4·5% [95% CI –9·5 to 
–0·1]; yellow fever, 1·2% [–2·9 to 5·5]; measles, 6·8% 
[95% CI –1·4 to 14·9]; poliovirus serotype 1, 1·6% [–6·7 to 
4·7]; serotype 2, 0·0% [–2·1 to 2·1]; serotype 3, 0·0% 
[–3·8 to 3·9]; ﬁ gure 2, appendix). The median antibody 
titre increased to 512 for poliovirus types 1 and 2 across 
all groups and to between 768 and 1024 for poliovirus 
type 3. The corresponding non-inferiority analysis for 
diﬀ erences in antibody titre (TINV–TREF) is illustrated in 
ﬁ gure 2; the corresponding ﬁ gures are given in the 
IPV Measles–rubella Yellow fever IPV and 
measles–rubella
IPV and yellow 
fever
Measles–rubella 
and yellow fever
IPV, 
measles–rubella, 
and yellow fever
Poliovirus type 1
Seroprevalence 160/182, 87·9% 
(82·4–91·9)
·· ·· 162/181, 89·5% 
(84·2–93·2)
162/176, 92·0% 
(87·1–95·2)
·· 159/184, 86·4% 
(80·7–90·6)
Antibody titres 64 (64–128) ·· ·· 64 (64–64) 128 (64–128) ·· 64 (64–114)
Poliovirus type 2
Seroprevalence 174/182, 95·6% 
(91·6–97·8)
·· ·· 174/181, 96·1% 
(92·2–98·1)
171/176, 97·2% 
(93·5–98·8)
·· 178/184, 96·7% 
(93·1–98·5)
Antibody titres 64 (64–128) ·· ·· 128 (64–128) 128 (64–128) ·· 64 (64–128)
Poliovirus type 3
Seroprevalence 130/182, 71·4% 
(64·5–77·5)
·· ·· 139/181, 76·8% 
(70·1–82·3)
151/176, 85·8% 
(79·9–90·2)
·· 133/184, 72·3% 
(65·4–78·2)
Antibody titres 32 (16–64) ·· ·· 32 (16–32) 64 (32–64) ·· 32 (16–32)
Measles
Seroprevalence ·· 1/183, 0·5% 
(0·1–3·0)
·· 2/181, 1·1% 
(0·3–3·9)
·· 2/182, 1·1% 
(0·3–3·9)
0/185, 0·0% 
(0·0–2·0)
Antibody titres ·· <150 
(<150–<150)
·· <150 
(<150–<150)
·· <150 
(<150–<150)
<150 
(<150–<150)
Rubella
Seroprevalence ·· 16/183, 8·7% 
(5·5–13·7)
·· 20/181, 11·0% 
(7·3–16·5)
·· 25/182, 13·7% 
(9·5–19·5)
24/185, 13·0% 
(8·9–18·6)
Antibody titres ·· <4 (<4–<4) ·· <4 (<4–<4) ·· <4 (<4–<4) <4 (<4–<4)
Yellow fever
Seroprevalence ·· ·· 4/180, 2·2% 
(0·9–5·6)
·· 3/175, 1·7% 
(0·6–4·9)
5/182, 2·7% 
(1·2–6·3)
3/185, 1·6% 
(0·6–4·7)
Antibody titres ·· ·· <4 (<4–<4) ·· <4 (<4–<4) <4 (<4–<4) <4 (<4–<4)
Data are median (95% CI) or n/N, % (95% CI). Seroprevalence is deﬁ ned as follows: poliovirus types 1, 2, and 3, reciprocal neutralising antibody titre ≥8; measles, antibody 
concentration ≥150 IU/mL; rubella, antibody concentration ≥4 IU/mL; yellow fever, reciprocal neutralising antibody titre ≥8. Denominators diﬀ er from number of infants due 
to missing serological results for one or other antigen. IPV=inactivated poliovirus vaccine.
Table 2: Baseline serology in the per-protocol population examined for vaccine interference 
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IPV (n=182) Measles–rubella 
(n=183)
Yellow fever 
(n=180)
IPV and 
measles–rubella 
(n=181)
IPV and yellow 
fever (n=175)
Measles–rubella 
and yellow 
fever (n=182)
IPV, 
measles–rubella, 
and yellow fever 
(n=184)
Poliovirus type 1
Seroprevalence 179/182, 98·4% 
(95·3–99·4)
·· ·· 178/181, 98·3% 
(95·2–99·4)
175/175, 100·0% 
(97·9–100·0)
·· 184/184, 100·0% 
(98·0–100·0)
Antibody titres 512 (512–512) ·· ·· 512 (512–512) 512 (512–512) ·· 512 (512–512)
Seroconversion 19/22, 86·4% 
(66·7–95·3)
·· ·· 16/19, 84·2% 
(62·4–94·5)
14/14, 100·0% 
(78·5–100·0)
·· 25/25, 100·0% 
(86·7–100·0)
Four-fold rise 100/160, 62·5% 
(54·8–69·6)
·· ·· 117/162, 72·2% 
(64·9–78·5)
98/161, 60·9% 
(53·2–68·1)
·· 103/159, 64·8% 
(57·1–71·8)
Total response 119/182, 65·4% 
(58·2–71·9)
·· ·· 133/181, 73·5% 
(66·6–79·4)
112/175, 64·0% 
(56·7–70·7)
·· 128/184, 69·6% 
(62·6–75·8)
Poliovirus type 2
Seroprevalence 182/182, 100·0% 
(97·9–100·0)
·· ·· 181/181, 100·0% 
(97·9–100·0)
175/175, 100·0% 
(97·9–100·0)
·· 184/184, 100·0% 
(98·0–100·0)
Antibody titres 512 (512–512) ·· ·· 512 (256–512) 512 (512–512) ·· 512 (512–512)
Seroconversion 8/8, 100·0% 
(67·6–100·0)
·· ·· 7/7, 100·0% 
(64·6–100·0)
5/5, 100·0% 
(56·6–100·0)
·· 6/6, 100·0% 
(61·0–100·0)
Four-fold rise 121/174, 69·5% 
(62·3–75·9)
·· ·· 113/174, 64·9% 
(57·6–71·6)
111/170, 65·3% 
(57·9–72·0)
·· 119/178, 66·9% 
(59·6–73·3)
Total response 129/182, 70·9% 
(63·9–77·0)
·· ·· 120/181, 66·3% 
(59·1–72·8)
116/175, 66·3% 
(59·0–72·9)
·· 125/184, 67·9% 
(60·9–74·3)
Poliovirus type 3
Seroprevalence 177/182, 97·3% 
(93·7–98·8)
·· ·· 178/181, 98·3% 
(95·2–99·4)
174/175, 99·4% 
(96·8–99·9)
·· 179/184, 97·3% 
(93·8–98·8)
Antibody titres 768 (512–1024) ·· ·· 1024 (512–1024) 1024 (1024–1024) ·· 1024 (512–1024)
Seroconversion 47/52, 90·4% 
(79·4–95·8)
·· ·· 39/42, 92·9% 
(81·0–97·5)
24/25, 96·0% 
(80·5–99·3)
·· 46/51, 90·2% 
(79·0–95·7)
Four-fold rise 109/130, 83·8% 
(76·6–89·2)
·· ·· 115/139, 82·7% 
(75·6–88·1)
121/150, 80·7% 
(73·6–86·2)
·· 115/133, 86·5% 
(79·6–91·3)
Total response 156/182, 85·7% 
(79·9–90·1)
·· ·· 154/181, 85·1% 
(79·2–89·5)
145/175, 82·9% 
(76·6–87·7)
·· 161/184, 87·5% 
(81·9–91·5)
Measles
Seroprevalence ·· 141/183, 77·0% 
(70·4–82·5)
·· 141/181, 77·9% 
(71·3–83·3)
·· 143/182, 78·6% 
(72·1–83·9)
154/184, 83·7% 
(77·7–88·3)
Antibody titres ·· 250 (230–280) ·· 240 (220–260) ·· 270 (243–310) 250 (230–290)
Seroconversion ·· 140/182, 76·9% 
(70·3–82·4)
·· 139/179, 77·7% 
(71·0–83·1)
·· 142/180, 78·9% 
(72·4–84·2)
154/184, 83·7% 
(77·7–88·3)
Four-fold rise ·· 1/1, 100·0% 
(20·7–100·0)
·· 0/2, 0·0% 
(0·0–65·8)
·· 0/2, 0·0% 
(0·0–65·8)
0/0
Total response ·· 83/141, 77·0% 
(70·4–82·5)
·· 81/139 76·8% 
(70·1–82·3)
·· 82/142, 78·0% 
(71·5–83·4)
84/154 83·7% 
(77·7–88·3)
Rubella
Seroprevalence ·· 180/183, 98·4% 
(95·3–99·4)
·· 174/181, 96·1% 
(92·2–98·1)
·· 176/182, 96·7% 
(93·0–98·5)
174/184, 94·6% 
(90·3–97·0)
Antibody titres ·· 31 (27–36) ·· 27 (21–33) ·· 27 (24–31) 24 (20–29)
Seroconversion ·· 164/167, 98·2% 
(94·9–99·4)
·· 154/161, 95·7% 
(91·3–97·9)
·· 152/157, 96·8% 
(92·8–98·6)
150/160, 93·8% 
(88·9–96·6)
Four-fold rise ·· 0/16, 0·0% 
(0·0–19·4)
·· 0/20, 0·0% 
(0·0–16·1)
·· 0/25, 0·0% 
(0·0–13·3)
0/24, 0·0% 
(0·0–13·8)
Total response ·· (83/164, 89·6% 
(84·4–93·3)
·· 81/154, 85·1% 
(79·2–89·5)
·· 82/152, 83·5% 
(77·4–88·2)
84/150, 81·5% 
(75·3–86·5)
Yellow fever
Seroprevalence ·· ·· 173/180, 96·1% 
(92·2–98·1)
·· 169/175, 96·6% 
(92·7–98·4)
173/182, 95·1% 
(90·9–97·4)
179/184, 97·3% 
(93·8–98·8)
Antibody titres ·· ·· 128 (91–128) ·· 91 (91–128) 64 (64–91) 64 (45–64)
(Table 3 continues on next page)
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appendix. Finally, examining the total response, 
including the proportion of infants who seroconverted 
and the proportion who had a four-fold rise in antibody 
titres (table 3), gave no indication that vaccine co-
administration interfered with the poliovirus-speciﬁ c 
responses.
Seroconversion rates for measles ranged from 
77% to 84%. There was no evidence that vaccine 
co-administration negatively aﬀ ected either the 
seroconversion rates or the post-vaccination measles 
antibody concentrations. For both outcomes, non-
inferiority of the responses against the prespeciﬁ ed 
margins was demonstrated (ﬁ gure 2, appendix). In total, 
98% of infants who received the measles–rubella 
vaccine alone seroconverted to rubella, whereas 94% 
seroconverted when all three vaccines were administered 
together. Non-inferiority was nonetheless demonstrated 
against the –10% non-inferiority margin. Rubella-speciﬁ c 
antibody concentrations were reduced by vaccine 
co-administration and did not achieve non-inferiority, 
irrespective of whether measles–rubella vaccine was 
co-administered with one or both of the additional 
vaccines; although interference was most marked when 
all three vaccines were given together (ﬁ gure 2, 
appendix).
The seroconversion rates for yellow fever vaccine 
ranged from 95% to 97%, and were unaﬀ ected by 
vaccine co-administration. However, the yellow fever 
median antibody titre was 128 (95% CI 91–128) when 
the vaccine was administered on its own, while it was 
only 64 (95% CI 45–64) and was inferior when all three 
vaccines were administered together (ﬁ gure 2, 
appendix). The same trend was demonstrated when 
yellow fever vaccine was administered with either the 
IPV vaccine or the measles–rubella vaccine alone, 
and non-inferiority was not demonstrated for any 
combination.
Applying the intersection union test,19 global 
non-inferiority was demonstrated for all vaccine 
combinations when examining seroprevalence and 
seroconversion rates. By contrast, when examining 
antibody titres, no vaccine combination achieved global 
non-inferiority, reﬂ ecting the reduction in both the rubella 
and yellow fever titres associated with co-administration.
The baseline and post-vaccination serological data for 
the four groups considered in the assessment of the 
fractional dosing and IPV administration with 
disposable-syringe jet injector (objective two) are 
provided in tables 4 and 5, respectively. Post-vaccination 
IPV (n=182) Measles–rubella 
(n=183)
Yellow fever 
(n=180)
IPV and 
measles–rubella 
(n=181)
IPV and yellow 
fever (n=175)
Measles–rubella 
and yellow 
fever (n=182)
IPV, 
measles–rubella, 
and yellow fever 
(n=184)
(Continued from previous page)
Seroconversion ·· ·· 169/176, 96·0% 
(92·0–98·1)
·· 166/172, 96·5% 
(92·6–98·4)
168/177, 94·9% 
(90·6–97·3)
176/181, 97·2% 
(93·7–98·8)
Four-fold rise ·· ·· 3/4, 75·0% 
(30·1–95·4)
·· 2/3, 66·7% 
(20·8–93·9)
4/5, 80·0% 
(37·6–96·4)
2/3, 66·7% 
(20·8–93·9)
Total response ·· ·· 172/180, 95·6% 
(91·5–97·7)
·· 168/175, 96·0% 
(92·0–98·0)
172/182, 94·5% 
(90·2–97·0)
178/184, 96·7% 
(93·1–98·5)
Data are median (95% CI) or n/N, % (95% CI). Seroprevalence is deﬁ ned as follows: poliovirus types 1, 2, and 3, reciprocal neutralising antibody titre ≥8; measles, antibody 
concentration ≥150 IU/mL; rubella, antibody concentration ≥4 IU/mL; yellow fever, reciprocal neutralising antibody titre ≥8; seroconversion is deﬁ ned for all antigens as a 
change from seronegative baseline to seropositive after vaccination and is expressed as a percentage of those individuals who were seronegative at baseline. Four-fold rise is 
deﬁ ned as follows: poliovirus types 1, 2, and 3, a four-fold rise in antibody titres amongst those infants who were seropositive at baseline; measles and rubella, a four-fold rise 
in antibody concentrations amongst those infants who were seropositive at baseline; yellow fever, a four-fold rise in antibody titres amongst those infants who were 
seropositive at baseline with an antibody titre of ≤64. Total response includes the number of subjects who underwent seroconversion and the number who had a four-fold 
rise (as previously deﬁ ned). IPV=inactivated poliovirus vaccine. 
Table 3: Post-vaccination serology in the per-protocol population examined for vaccine interference
Figure 2: Vaccine co-administration (objective one)
(A) Diﬀ erences in the seroprevalence for poliovirus types 1, 2, and 3 seroconversion for measles, rubella, and yellow 
fever, comparing each of the vaccines administered on its own with the combination of all three vaccines 
administered together. Circles represent the point estimate, lines are 95% CIs. (B) Diﬀ erence in the antibody titres 
comparing each of the vaccines administered on its own with the combination of all three vaccines administered 
together. Circles represent the point estimate, lines are 95% CIs.
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seroprevalence ranged from 97% to 99% for type 1 and 
from 99% to 100% for type 2. The three alternative 
routes of administration were consistently non-inferior 
for these outcomes (ﬁ gure 3, appendix). Poliovirus 
serotype 3 seroprevalence achieved non-inferiority for 
the intradermal needle and syringe administration 
but did not achieve non-inferiority after intradermal 
administration using the disposable-syringe jet injector 
(SINV–SREF –5·66% [95% CI –10·60 to –1·31]). 
Non-inferiority of the median antibody titres was not 
achieved by any of the alternative routes (ﬁ gure 3B, 
appendix). Furthermore, the titres generated after the 
primary analysis of intradermal needle and syringe 
administration were inferior for serotype 3 and 
after the analysis of intradermal administration with 
disposable-syringe jet injector were inferior for all 
serotypes. Overall, two-thirds of infants either 
seroconverted or had a four-fold rise in antibody titres 
after intramuscular needle and syringe (67%) or 
disposable-syringe jet injector (66%) administration, 
compared with 56% and 44% after the equivalent 
intradermal routes. The same pattern was seen for the 
type 2 and type 3 polioviruses (table 5). A secondary 
non-inferiority analysis of these total responses is 
provided in the appendix.
A modiﬁ ed intention-to-treat analysis (including 
1277 [97%] of 1314 infants for analysis of objective one; and 
711 [94%] of 754 infants for analysis of objective two) was 
done in all infants in whom serological endpoints were 
measured outside the speciﬁ ed visit windows any other 
minor protocol deviations resulted in the same statistical 
inference as the per-protocol analysis (data not shown).
A total of 36 serious adverse events occurred in 
35 infants enrolled in the trial. Three infants died, two 
of whom were hospitalised at the time. None of the 
deaths were deemed related to vaccination by the data 
safety and monitoring board. One serious adverse event 
was deﬁ ned as possibly related to yellow fever 
vaccination. The infant developed a signiﬁ cant rash 
IPV intramuscular, 
needle and syringe 
(n=178)
IPV intramuscular, 
disposable-syringe 
jet injector (n=168)
IPV intradermal, 
needle and syringe 
(n=177)
IPV intradermal, 
disposable-syringe 
jet injector (n=177)
Poliovirus type 1
Seroprevalence 155/178, 87·1% 
(81·4–91·2)
151/168, 89·9% 
(84·4–93·6)
152/177, 85·9% 
(80·0–90·2)
159/177, 89·8% 
(84·5–93·5)
Antibody titres 64 (46–128) 64 (32–64) 64 (64–128) 64 (64–128)
Poliovirus type 2
Seroprevalence 171/178, 96·1% 
(92·1–98·1)
166/168, 98·8% 
(95·8–99·7)
173/177, 97·7% 
(94·3–99·1)
175/177, 98·9% 
(96·0–99·7)
Antibody titres 64 (64–128) 128 (64–128) 64 (64–128) 64 (64–65)
Poliovirus type 3
Seroprevalence 142/178, 79·8% 
(73·3–85·0)
139/168, 82·7% 
(76·3–87·7)
131/177, 74·0% 
(67·1–79·9)
134/177, 75·7% 
(68·9–81·4)
Antibody titres 32 (32–32) 32 (32–64) 16 (16–32) 32 (16–64)
Data are median (95% CI) or n/N, % (95% CI). Seroprevalence is deﬁ ned as a reciprocal neutralising antibody titre ≥8. 
Table 4: Baseline serology in the per-protocol population comparing routes of administration
IPV intramuscular, needle and 
syringe (n=178)
IPV intramuscular, disposable-
syringe jet injector (n=168)
IPV intradermal, needle and 
syringe (n=177)
IPV intradermal, disposable-
syringe jet injector (n=177)
Poliovirus type 1
Seroprevalence 175/178; 98·3% (95·2–99·4) 167/168; 99·4% (96·7–99·9) 174/177; 98·3%, (95·1–99·4) 172/177; 97·2% (93·6–98·8)
Antibody titres 512 (256–512) 512 (256–512) 256 (256–256) 256 (128–256)
Seroconversion 20/23; 87·0% (67·9–95·5) 16/17; 94·1% (73·0–99·0) 22/25; 88·0% (70·0–95·8) 13/18; 72·2% (49·1–87·5)
Four-fold rise 99/155; 63·9% (56·1–71·0) 95/151; 62·9% (55·0–70·2) 77/152; 50·7% (42·8–58·5) 64/159; 40·3% (32·9–48·0)
Total response 119/178; 66·9% (59·6–73·3) 111/168; 66·1% (58·6–72·8) 99/177; 55·9% (48·6–63·0) 77/177; 43·5% (36·4–50·9)
Poliovirus type 2
Seroprevalence 177/178; 99·4% (96·9–99·9) 168/168; 100·0% (97·8–100·0) 175/177; 98·9% (96·0–99·7) 177/177; 100·0% (97·9–100·0)
Antibody titres 512 (512–512) 512 (256–512) 256 (256–512) 256 (128–256)
Seroconversion 6/7; 85·7% (48·7–97·4) 2/2; 100·0% (34·2–100·0) 2/4; 50·0% (15·0–85·0) 2/2; 100·0% (34·2–100·0)
Four-fold rise 123/171; 71·9% (64·8–78·1) 98/166; 59·0% (51·4–66·2) 101/173; 58·4% (50·9–65·5) 72/175; 41·1% (34·1–48·5)
Total response 129/178; 72·5% (65·5–78·5) 100/168; 59·5% (52·0–66·7) 103/177; 58·2% (50·8–65·2) 74/177; 41·8% (34·8–49·2)
Poliovirus type 3
Seroprevalence 175/178; 98·3% (95·2–99·4) 162/168; 96·4% (92·4–98·4) 167/177; 94·4% (89·9–96·9) 164/177; 92·7% (87·8–95·7)
Antibody titres 1024 (512–1024) 512 (512–1024) 512 (512–512) 256 (256–512)
Seroconversion 33/36; 91·7% (78·2–97·1) 23/29; 79·3% (61·6–90·2) 37/46; 80·4% (66·8–89·3) 30/43; 69·8% (54·9–81·4)
Four-fold rise 114/142; 80·3% (73·0–86·0) 113/139; 81·3% (74·0–86·9) 105/131; 80·2% (72·5–86·1) 93/134; 69·4% (61·2–76·6)
Total response 147/178; 82·6% (76·3–87·5) 136/168; 81·0% (74·3–86·2) 142/177; 80·2% (73·7–85·4) 123/177; 69·5% (62·4–75·8)
Data are median (95% CI) or n/N, % (95% CI). Seroprevalence is deﬁ ned as a reciprocal neutralising antibody titre ≥8; seroconversion is deﬁ ned as a change from seronegative at 
baseline to seropositive after vaccination and is expressed as a percentage of those individuals who were seronegative at baseline; four-fold rise is deﬁ ned a four-fold rise in 
antibody titres amongst those infants who were seropositive at baseline; total response includes the number of participants who underwent seroconversion and the number who 
had a four-fold rise (as previously deﬁ ned). 
Table 5: Post-vaccination serology in the per-protocol population comparing routes of administration
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within 24 h of vaccination, although contact dermatitis 
related to an antiseptic wash was ultimately judged to be 
more likely.
All vaccinations were well tolerated, with a low level of 
local and systemic reactogenicity being recorded overall. 
At the day three home visit after visit one, redness, 
swelling, or tenderness occurred in nine infants after 
IPV, six infants after measles–rubella, and ﬁ ve infants 
after yellow fever vaccine administration. At visit two, 
there were no clinically signiﬁ cant immediate local 
reactions related to IPV delivery, irrespective of delivery 
route. Both devices were easy to use and reliable. Over 
the ﬁ rst 3 days, redness, swelling, or tenderness was 
recorded in two infants who received the intramuscular 
vaccine using a needle and syringe, ﬁ ve who received it 
intramuscularly using the disposable-syringe jet injector, 
three who received it intradermally using a needle and 
syringe, and three who received it intradermally using 
the disposable-syringe jet injector. All local reactogenicity 
was mild and had resolved by the day three home visit. 
All systemic reactogenicity was mild or moderate 
(appendix), and there were no notable diﬀ erences related 
to treatment group .
Discussion
To our knowledge, this is the ﬁ rst trial to examine the 
co-administration of IPV with the measles–rubella and 
yellow fever vaccines, or to examine co-administration of 
the measles–rubella and yellow fever vaccines together. It 
provides the key data required before any future 
introduction of IPV into the EPI schedule alongside the 
measles–rubella and yellow fever vaccines at 9 months of 
age. Although co-administration resulted in a signiﬁ cant 
reduction in the antibody titres generated against both 
rubella and yellow fever, seroconversion rates were 
maintained above the –10% non-inferiority margin in both 
cases. There was no evidence of interference with the 
immunity generated against either the polioviruses or the 
measles component of the combined vaccine and there 
were no safety concerns.
The measles–rubella vaccine is universally recom-
mended by WHO for infants aged 9–12 months. The 
switch from the single-component measles vaccine is 
currently underway across sub-Saharan Africa and has 
recently occurred in The Gambia. The yellow fever 
vaccine is recommended for all children living in 
endemic countries across sub-Saharan Africa and 
Figure 3: Alternative routes of administration (objective two)
(A) Diﬀ erences in the seroprevalence for poliovirus types 1, 2, and 3 comparing full-dose IPV administered intramuscularly with a needle and syringe to the 
administration of a full dose of the same vaccine intramuscularly using a disposable-syringe jet injector, a fractional (0·1 mL) dose intradermally using a needle and 
syringe, and a fractional dose intradermally using a disposable-syringe jet injector. Circles represent the point estimate. (B) Diﬀ erence in the median antibody titres 
comparing the same alternative routes of administration with the reference full dose (administration intramuscularly with needle and syringe). Circles represent the 
point estimate. 
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South America. Thus, the data generated in this trial, 
representing a typical setting and population in 
west Africa, have direct implications for vaccine policy 
across these parts of the world, most of which currently 
also include OPV within their EPI schedule. Findings 
from a meta-analysis suggest that a single dose of IPV 
given at around 4 months of age will protect about half of 
recipients, whereas two doses given at an interval will 
provide at least 80% protection and hence is expected to 
be recommended before ﬁ nal OPV cessation.4 The 
administration of the second dose of IPV at 9 months of 
age, alongside the measles–rubella and yellow fever 
vaccines, is likely to generate more sustained protection 
than two doses given within the infant priming 
schedule.20
Reduced seroconversion rates to yellow fever 
and rubella have been demonstrated following the 
co-administration of the three-component measles, 
mumps, and rubella vaccine with the yellow fever 
vaccine.21 By contrast, those studies examining the 
co-administration of the single-component measles 
vaccine and the yellow fever vaccine have consistently 
demonstrated a lack of interference in the same age 
group.13,17,18 Findings from this study demonstrate that, 
although measles–rubella and yellow fever vaccine 
co-administration is associated with a reduction in the 
rubella and yellow fever antibody levels, which are 
further compromised on the addition of IPV, 
seroconversion rates are maintained to both antigens.
Mathematical modelling suggests that the risk of 
congenital rubella syndrome might be increased, 
through shifting the age of infection in susceptible 
females into their childbearing years, as a result of 
suboptimal vaccine coverage or response rates.22 The 
9–14% baseline rubella seroprevalence in 9-–10-month-
old infants in this study suggests signiﬁ cant levels of 
rubella infection over the ﬁ rst year of life in The Gambia. 
This is also likely to reﬂ ect maternal exposure over the 
same time period when further pregnancies are also 
common. Nonetheless, in view of the relative 
maintenance of the rubella seroconversion rates and 
the booster dose of the measles–rubella vaccine 
recommended in the second year of life, the reduced 
antibody concentrations in isolation do not seem to 
preclude future co-administration.
Primary yellow fever vaccine failure is exceptionally 
rare and, in view of the seroconversion rates demonstrated 
in all groups, is unlikely to be aﬀ ected by co-
administration. The long-term stability of the yellow 
fever antibody titres generated by vaccination means that 
secondary failures are also currently almost unheard of.23 
Whether the reduction in titres demonstrated will 
compromise the lifelong immunity needed in light of the 
recent WHO recommendation that only a single dose of 
the vaccine be included within the EPI schedule at 
9 months necessitates monitoring if such a schedule 
becomes established.23
Irrespective of timing, supply constraints and the cost 
of the vaccine make fractional dosing and disposable-
syringe jet-injector admin istration attractive options for 
both campaign and programmatic delivery.1 In the 
context of a high baseline seroprevalence, reﬂ ecting 
previous OPV immunisation, the post-vaccination 
seroprevalence rates were non-inferior to full-dose 
intramuscular needle and syringe administration, with 
the exception of the intradermal disposable-syringe jet 
injector for the type 3 poliovirus. By contrast, the 
neutralising antibody titres did not achieve non-
inferiority for any comparison with the full-dose 
intramuscular IPV. The proportion of infants who 
either seroconverted or who had a four-fold rise in 
antibody titres was also consistently lower by the 
intradermal route.
This is the ﬁ rst trial to explore the use of fractional 
doses of IPV in sub-Saharan Africa and provides key data 
relevant to this setting. The ﬁ ndings are consistent with 
trials that have examined the use of fractional doses of 
IPV in OPV-primed toddlers elsewhere.5,9 A single 
fractional intradermal dose of IPV in an OPV-vaccinated 
population will result in seroconversion in most infants 
who remain seronegative despite multiple doses of OPV. 
This may be adequate for outbreak control or campaign 
use, when injector-based administration might also oﬀ er 
practical advantages. Although the neutralising antibody 
titres generated by IPV could be maintained for more 
than 30 years, this is likely to be compromised by lower 
initial titres.24 Memory responses persist even in the 
absence of detectable antibody, but it is unknown 
whether these translate into sustained protection.4 Thus, 
research aiming to enhance IPV immunogenicity 
through, for example, the use of novel adjuvants and new 
technologies (eg, dissolvable microneedles1) remains a 
priority if fractional dosing is to become routine.
Several limitations of the trial and the future 
application of the results should be considered. First, the 
study was undertaken in a trivalent OPV primed 
population rather than a population primed with bivalent 
OPV and IPV. Although the post-vaccination 
seroprevalence rates were high after the fractional 
intradermal doses of IPV and after the injector-based 
administration, data indicate these ﬁ gures and the 
resulting antibody titres are likely to be a conservative 
estimate of the response to a booster, rather than a 
primary IPV dose.10,25 Second, when examining the 
poliovirus titres, there are a number of examples where 
non-inferiority was not demonstrated despite the point 
estimate for the diﬀ erence being close to zero. Thus, 
care must be exercised in interpreting the outcome of 
non-inferiority testing in isolation without examining 
the associated titre diﬀ erences. Similarly, a number of 
chance diﬀ erences in baseline poliovirus titres are 
present and should be noted. Thirdly, safety data was not 
collected in a blinded fashion and although the context 
and absence of any consistent trends suggests substantial 
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bias is unlikely, this possibility should nonetheless be 
recognised. Finally, the trial design did not include a 
second randomisation step at visit two. Thus, the 
possibility of some residual eﬀ ect of the vaccines 
administered at visit one on the responses to IPV 
administered at visit two is acknowledged. We are not 
aware of data to indicate that this possibility is anything 
more than a theoretical concern.
In conclusion, our trial ﬁ ndings have direct policy 
implications for the polio eradication endgame given the 
expected need to introduce a second dose of IPV into the 
schedule in those parts of the world at risk of outbreaks 
after OPV cessation. In view of the global non-inferiority 
of the response rates demonstrated and the lack of safety 
signals, the ﬁ ndings support the future co-administration 
of the IPV, measles–rubella, and yellow fever vaccines, 
although ongoing monitoring of rubella and yellow fever 
seroprevalence is warranted if such a programme 
becomes established. The use of fractional intradermal 
doses of IPV, irrespective of method of administration, 
will result in a high post-vaccination seroprevalence and, 
as recently endorsed by WHO,26 remains an option for 
an outbreak response. However, such approaches 
substantially compromise the polio-speciﬁ c immunity 
generated and—supply constraints and costs 
acknowledged—are not supported as a single dose 
routine approach on the basis of these ﬁ ndings.
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